drugset / Trial / NCT01130025

Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

NCT01130025

Phase 3 Completed 900 enrolled LEO Pharma
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and safety of Innohep® in preventing the recurrence of VTE in patients with active cancer who have had an acute VTE episode.

Timeline

Start
2010-08
Primary completion
2014-04
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Tinzaparin Other / unclassified 175 iu/kg Subcutaneous
Comparator Warfarin Small molecule Oral